Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 agonist, but it also ...

Subcutaneous amycretin featured a safety profile similar to other incretin-based drugs in a phase 1b/2a trial. Adults with obesity lost more weight with 1.25 mg, 5 mg and 20 mg amycretin vs.

Amycretin trial showed weight loss of 9.7% to 22% over 36 weeks at varying doses, compared to weight gain with placebo. Common side effects were mild-to-moderate gastrointestinal issues, aligning ...

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

If you continue to have this issue please contact [email protected]. Back to Healio Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with ...

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug. The trial showed average weight ...

Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug. The trial showed average weight ...